MANA Advisors LLC acquired a new position in TherapeuticsMD Inc (NASDAQ:TXMD) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,256 shares of the company’s stock, valued at approximately $104,000.
A number of other large investors have also modified their holdings of the stock. Geode Capital Management LLC boosted its holdings in TherapeuticsMD by 19.7% during the fourth quarter. Geode Capital Management LLC now owns 1,606,780 shares of the company’s stock valued at $9,704,000 after acquiring an additional 264,421 shares during the period. Sphera Funds Management LTD. boosted its holdings in TherapeuticsMD by 26.3% during the fourth quarter. Sphera Funds Management LTD. now owns 479,980 shares of the company’s stock valued at $2,899,000 after acquiring an additional 99,980 shares during the period. OppenheimerFunds Inc. boosted its holdings in TherapeuticsMD by 10.8% during the fourth quarter. OppenheimerFunds Inc. now owns 1,634,080 shares of the company’s stock valued at $9,870,000 after acquiring an additional 158,943 shares during the period. BlackRock Inc. boosted its holdings in TherapeuticsMD by 29.7% during the fourth quarter. BlackRock Inc. now owns 14,431,862 shares of the company’s stock valued at $87,169,000 after acquiring an additional 3,307,477 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in TherapeuticsMD by 12.0% during the fourth quarter. Bank of New York Mellon Corp now owns 28,973,668 shares of the company’s stock valued at $175,001,000 after acquiring an additional 3,095,804 shares during the period. Hedge funds and other institutional investors own 73.28% of the company’s stock.
TherapeuticsMD Inc (NASDAQ TXMD) opened at $5.24 on Thursday. TherapeuticsMD Inc has a 52-week low of $3.50 and a 52-week high of $8.30. The stock has a market cap of $1,130.00, a PE ratio of -13.79 and a beta of 1.13.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Tuesday, February 20th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.01). TherapeuticsMD had a negative return on equity of 63.67% and a negative net margin of 458.49%. The business had revenue of $4.13 million during the quarter, compared to analyst estimates of $4.66 million. During the same period last year, the company earned ($0.12) EPS. The business’s revenue for the quarter was down 8.0% on a year-over-year basis. equities research analysts anticipate that TherapeuticsMD Inc will post -0.38 earnings per share for the current fiscal year.
TXMD has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated a “buy” rating and set a $31.00 price target on shares of TherapeuticsMD in a report on Wednesday, November 29th. Noble Financial reaffirmed a “buy” rating on shares of TherapeuticsMD in a research report on Thursday, November 30th. BidaskClub raised shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 12th. Deutsche Bank set a $9.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, December 20th. Finally, Oppenheimer set a $10.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Wednesday, December 20th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $14.50.
TRADEMARK VIOLATION WARNING: This report was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://ledgergazette.com/2018/03/15/mana-advisors-llc-invests-104000-in-therapeuticsmd-inc-txmd.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.